OSIRIS THERAPEUTICS INC. overview

VIDEO FINANCIAL REPORTING Why invest in is the first financial video platform where you can easily search through thousands of videos describing global ......

COLUMBIA, Md., Jan. 19, 2017 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR) announced today that the study “A Comparative Outcomes Analysis Evaluating Clinical Effectiveness in Two Different Human Placental Membrane Products for Wound Management” has been published in the peer-reviewed journal Wound Repair and Regeneration and is available online ( http://bit.ly/comparativeoutcomes ) . This is the first comparative effectiveness study to report on the clinical outcomes...

COLUMBIA, Md., Jan. 13, 2017 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR), announced today that a new peer-reviewed manuscript “Human cryopreserved viable amniotic membrane inhibits the growth of bacteria associated with chronic wounds” (Mao et al.) has been published in the Journal of Diabetic Foot Complications and available online . Chronic wounds are on the rise and represent an enormous financial burden to the patient and to the healthcare system. Wound related infection...

COLUMBIA, Md., Dec. 02, 2016 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR) (the “Company”) today provided an update regarding the status of its compliance with the Listing Rules of the NASDAQ Stock Market (“NASDAQ”). As previously disclosed, the Company participated in a hearing before the NASDAQ Hearings Panel (the “Hearings Panel”) on November 10, 2016 in connection with the Company’s late filings and the Company’s anticipated financial restatement relating to...

COLUMBIA, Md., Nov. 22, 2016 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR) announced today that a new peer-reviewed manuscript by physician and surgeon Jonathan Smedley, DPM, FACFAS, entitled “Wound Closure in Smoking Peripheral Arterial Disease Patients with Treatment Refractory Ulcerations: A 12-month Follow-up Case Series,” has been published in the International Journal of Lower Extremity Wounds and is available on-line. A 1-year, single-center effectiveness review was...

COLUMBIA, Md., Nov. 21, 2016 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR) (the “Company”) today provided an update regarding the status of its compliance with the Listing Rules of the NASDAQ Stock Market (“NASDAQ”). As previously disclosed, the Company received notifications from NASDAQ indicating that, as a result of the Company not timely filing with the Securities and Exchange Commission (“SEC”) its Annual Report on Form 10-K for the year ended December 31, 2015 and...

COLUMBIA, Md., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR), a leading regenerative medicine company focused on developing and marketing products for wound care, orthopaedics, and sports medicine, today announced its preliminary revenue estimates for 2014 and 2015 and its anticipated 2016 revenue. As previously announced, the Company is working diligently to complete the restatement of its 2014 financial statements as soon as possible. Once that process is complete,...

COLUMBIA, Md., Oct. 31, 2016 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR), a leading regenerative medicine company focused on developing and marketing products for wound care, orthopaedics and sports medicine, announced today that a new peer-reviewed manuscript by Kazu Suzuki, DPM, CWS, Surgeon, Certified Wound Care Specialist, “Viable intact cryopreserved human placental membrane for a non-surgical approach to closure in complex wounds” has been published in the Journal of...